Merck Ltd. and the government-funded Development Center for Biotechnology (DCB) jointly announced yesterday a cooperation agreement to establish an Asia Technology Training Center (ATTC) in Taiwan.
Merck will invest approximately NT$10 million (US$308,000) in the training center, bringing its own systems and plans to have two to three lab technicians in addition to a technical manager, who will be responsible for coordinating clients throughout Asia, said William Chen (
"The initial investment is small, but the potential return on capital is exponential," he said.
Since DCB will be providing a majority of the talent and support, Merck will have a smaller staff, Chen said.
"The key is our technical manager, who will have to act as coordinator for clients across Asia and rely on our expertise in scale production of protein-based drugs and consulting services," Chen said.
"The ATTC is not merely a training center; it is where clients can come and use our expertise and perhaps inquire about technology transfer," he said.
German-based Merck established its Taiwan branch in 1989 and distributes laboratory equipment and raw ingredients for research in sciences. The company has two training centers in the world -- one in Germany and another in the US. ATTC will be the third facility and the only one in Asia.
Under the agreement, Merck will set up ATTC on the DCB campus in Sijhih City (汐止), Taipei County. DCB will provide the space, facilities, consultants and supplies, while Merck will share its cooperation model with customers and partner DCB in its global R&D efforts.
The competition to house this facility was high, with Japan, China, India and South Korea all vying for the opportunity to enhance their biotechnology sector, DCB officials said.
"DCB is quite pleased to have won Merck's approval. The joint proposal drawn up by Merck Taiwan and DCB was done within a week and beat out proposals from other Asian countries -- some of which had been working on the proposals for a year," said Huang Bor-fuei (
DCB and Merck Taiwan were able to edge out the competition as their proposal went beyond the simple concept of a "training center" and incorporated more business integration opportunities, Huang said.
Taiwan has an advantage in this sector in Asia because of its clear rules on intellectual property rights protection, DCB's well-established bioprocessing team and R&D facilities, and a current good manufacturing practice, or CGMP, pilot plant to support large-scale production, he said.
DCB chairman Wu Shuh-min (
Wu was referring to the legislature's approval of the Biotech and New Pharmaceutical Development Act (
"It also shows that Merck recognizes the efforts DCB has made in 2007 on the international stage, striking cooperation deals with Boehringer Ingelheim of Germany, Crucell of Netherlands and MediVas of the United States," Wu said
Looking ahead, DCB, and by corollary, Taiwan's biotechnology industry, will benefit from more international exposure and recognition, and smaller biotech firms will gain access to world-class consulting and services in protein-based drug production, Huang said.
One of several Taiwanese biotechnology firms present at yesterday's event said it had learned more about potential opportunities to cooperate with DCB.
“The case put forward by DCB looks good, and if costs are acceptable we will probably seek to cooperate with them. The services that Merck and DCB provide certainly helps the process of protein-based drug production,” said
Cheng Li-ting (鄭力廷), a researcher at Sijhih-based Yeastern Biotech Co Ltd (益生生技).
Units of Intel Corp and Samsung Electronics Co are targeting to resume full operations of their Ho Chi Minh City plants by the end of next month, a move that could provide relief to global supply chains. Saigon Hi-Tech Park is helping its tenants, many of which are running at about 70 percent capacity, to operate fully next month, park deputy manager Le Bich Loan said in a phone interview. She did not elaborate on the steps the park is taking, particularly efforts at bringing back workers who fled to home provinces. The Ho Chi Minh City unit of Nidec Sankyo Corp,
CHIP CRUNCH: Apple’s woes show that even the king of the technology world is not immune from global shortages made worse by the COVID-19 pandemic Apple Inc is likely to slash its projected iPhone 13 production targets for this year by as many as 10 million units as prolonged chip shortages hit its flagship product, people with knowledge of the matter said. The company had expected to produce 90 million new iPhone models in the final three months of this year, but it is now telling manufacturing partners that the total would be lower because Broadcom Inc and Texas Instruments Inc are struggling to deliver enough components, the people said. Apple gets display parts from Texas Instruments, while Broadcom is its longtime supplier of wireless components. One Texas
EVA Airways Corp (長榮航空) and China Airlines Ltd (中華航空), the nation’s two major airlines, reported accelerated revenue growth in the third quarter compared with the previous two quarters, thanks to robust air cargo business. EVA Airways yesterday said sales for last quarter rose 40 percent year-on-year to NT$25.81 billion (US$917 million), compared with an increase of 25 percent in the second quarter and a fall of 35 percent in the first quarter. China Airlines said sales grew 39 percent to NT$34.6 billion in the third quarter, after gaining 10 percent in the second quarter and falling 14 percent in the first quarter. EVA
Hon Hai Precision Industry Co (鴻海精密) is embarking on a recruitment drive to hire 200,000 workers in Shenzhen, China, as it ramps up production of the new iPhone 13 series, Chinese business news outlet Eastmoney.com reported. Hon Hai is seeking to recruit those heading back to the city after China’s seven-day National Day holiday, which began on Oct. 1, to help churn out the estimated 100,000 iPhone 13s produced on the site each day, the report said. Following last month’s global release of the iPhone 13, Hon Hai entered its traditional peak season, and workers at its Chinese production sites are said